polatuzumab vedotin (Polivy) Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab after at least two prior therapies. The drug was developed by Genentech.   Wikipedia

Drug Pricing (per unit)

United States

$2454.0600 - $15000.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

acd22-vcmmae | acd79b-vcmmae | dcds-4501a | dcdt2980s | dcdt-2980s | fcu-2703 | fcu-2711 | pinatuzumab vedotin | polatuzumab vedotin | rg-7593 | rg-7596 | ro-5541072-000 | ro-5541077-000

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue